Effects of inhibition of urokinase-type plasminogen activator (u-PA) by amiloride in the cornea and tear fluid of eyes irradiated with UVB.

[1]  M. Crippa.  Urokinase-type plasminogen activator. , 2007, The international journal of biochemistry & cell biology.

[2]  J. Čejková,et al.  Dipeptidyl peptidase IV (DPPIV) activity in the tear fluid as an indicator of the severity of corneal injury: a histochemical and biochemical study. , 2004, Histology and histopathology.

[3]  D. Collen,et al.  Tissue‐type plasminogen activator: a historical perspective and personal account , 2004, Journal of thrombosis and haemostasis : JTH.

[4]  J. Čejková,et al.  UV Rays, the prooxidant/antioxidant imbalance in the cornea and oxidative eye damage. , 2004, Physiological research.

[5]  J. Hoover-Plow,et al.  The role of plasminogen in angiogenesis in vivo , 2003, Journal of thrombosis and haemostasis : JTH.

[6]  T. Nishida,et al.  Up-regulation of urokinase-type plasminogen activator in corneal epithelial cells induced by wounding. , 2003, Investigative ophthalmology & visual science.

[7]  P. Carmeliet,et al.  Urokinase, a constitutive component of the inflamed synovial fluid, induces arthritis , 2002, Arthritis research & therapy.

[8]  L. Rhodes,et al.  UVR-induced oxidative stress in human skin in vivo: effects of oral vitamin C supplementation. , 2002, Free radical biology & medicine.

[9]  C. Noorden.  Direct comparison of enzyme histochemical and immunohistochemical methods to localize an enzyme , 2002 .

[10]  K. K. Saxena,et al.  Topical amiloride solution accelerates healing of mechanical skin ulcers in albino rats. , 2000, Methods and findings in experimental and clinical pharmacology.

[11]  J. Tözsér,et al.  Plasminogen activator activity in tears after excimer laser photorefractive keratectomy. , 2000, Investigative ophthalmology & visual science.

[12]  A. K. Sood,et al.  Topical amiloride accelerates healing and delays neovascularization in mechanically produced corneal ulcers in rabbits. , 1999, Methods and findings in experimental and clinical pharmacology.

[13]  E. Skrzypczak‐Jankun,et al.  Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride. , 1999, Cancer biochemistry biophysics.

[14]  J. Zvárová,et al.  Comparative histochemical and biochemical studies on acid beta-galactosidase activity in the experimentally injured rabbit cornea and tear fluid using the sensitive substrate beta-galactoside-4-trifluoromethylumbelliferyl (HFC). , 1999, Histology and histopathology.

[15]  Z. Lojda.  The use of substrates with 7-amino-3-trifluoromethylcoumarine (AFC) leaving group in the localization of protease activities in situ. , 1996, Acta histochemica.

[16]  J. Čejková,et al.  The appearance of active plasminogen activator of urokinase type (u-PA) in the rabbit anterior eye segment irradiated by UVB rays. A histochemical and biochemical study. , 1995, Acta histochemica.

[17]  J. Čejková,et al.  The damaging effect of UV rays below 320 nm on the rabbit anterior eye segment. II. Enzyme histochemical changes and plasmin activity after prolonged irradiation. , 1995, Acta histochemica.

[18]  H. Petty,et al.  Human urokinase-type plasminogen activator primes neutrophils for superoxide anion release. Possible roles of complement receptor type 3 and calcium. , 1995, Journal of immunology.

[19]  B. Eley,et al.  Comparative histochemical, biochemical and immunocytochemical studies of cathepsin B in human gingiva. , 1994, Journal of periodontal research.

[20]  J. Čejková,et al.  Biochemical and histochemical studies of plasminogen activator of urokinase type (u-PA) activity. I. A simple rapid semiquantitative fluorescent method for its detection in the tear fluid. , 1993, Acta histochemica.

[21]  T. Nishida,et al.  Role of Urokinase Type Plasminogen Activator (u-PA) in Corneal Epithelial Migration , 1993, Thrombosis and Haemostasis.

[22]  A. Vaheri,et al.  REGULATION OF THE PERICELLULAR ACTIVATION OF PLASMINOGEN AND ITS ROLE IN TISSUE‐DESTRUCTIVE PROCESSES , 1992, Acta ophthalmologica. Supplement.

[23]  F. Kaneko,et al.  Changes in lipid peroxide levels and activity of reactive oxygen scavenging enzymes in skin, serum and liver following UVB irradiation in mice. , 1992, Life sciences.

[24]  J. Pelletier,et al.  Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage. , 1991, The Journal of rheumatology.

[25]  K. Kenyon,et al.  Pathogenesis of corneal epithelial defects: role of plasminogen activator. , 1991, Current eye research.

[26]  J. Calvete,et al.  Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). , 1991, The Journal of biological chemistry.

[27]  R. Tripathi,et al.  Localization of urokinase-type plasminogen activator in human eyes: an immunocytochemical study. , 1990, Experimental eye research.

[28]  J. Tözsér,et al.  Determination of plasminogen activator activities in normal and pathological human tears. The significance of tear plasminogen activators in the inflammatory and traumatic lesions of the cornea and the conjunctiva , 1990, Acta ophthalmologica.

[29]  R. Avery,et al.  Systemic amiloride inhibits experimentally induced neovascularization. , 1990, Archives of ophthalmology.

[30]  F. Semeraro,et al.  Analysis of fibronectin, plasminogen activators and plasminogen in tear fluid as markers of corneal damage and repair. , 1990, Experimental eye research.

[31]  R. Nordquist,et al.  Role of active oxygen species in corneal ulceration. Effect of hydrogen peroxide generated in situ. , 1990, Cornea.

[32]  J. Tözsér,et al.  Plasminogen activator activity and plasminogen independent amidolytic activity in tear fluid from healthy persons and patients with anterior segment inflammation. , 1989, Clinica chimica acta; international journal of clinical chemistry.

[33]  P. Neumann,et al.  Evidence for regulation of endothelial plasminogen-activating system by polymorphonuclear leukocyte elastase. , 1989, Thrombosis research.

[34]  M. Berman.  The pathogenesis of corneal epithelial defects , 1989, Acta ophthalmologica. Supplement.

[35]  A. Vaheri,et al.  Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants , 1989, The Journal of cell biology.

[36]  R. Tripathi,et al.  Distribution of tissue plasminogen activator in human and monkey eyes. An immunohistochemical study. , 1987, Ophthalmology.

[37]  P. Gudewicz,et al.  Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils. , 1987, Biochemical and biophysical research communications.

[38]  A. Gee,et al.  Urokinase: a chemotactic factor for polymorphonuclear leukocytes in vivo. , 1987, Journal of immunology.

[39]  D. Belin,et al.  Amiloride selectively inhibits the urokinase‐type plasminogen activator , 1987, FEBS letters.

[40]  F. Blasi,et al.  Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors , 1987, The Journal of cell biology.

[41]  K. Fujikawa,et al.  The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. , 1986, The Journal of biological chemistry.

[42]  R. Stephens,et al.  Rat mammary carcinoma cells secrete active collagenase and activate latent enzyme in the stroma via plasminogen activator , 1981, International journal of cancer.

[43]  A. Pearse.  Histochemistry: Theoretical and Applied , 1953 .